Philips reaffirms commitment to advanced molecular imaging at SNMMI 2016 Annual Meeting

June 10, 2016

Showcasing solutions that highlight 125 years of continuous innovation in diagnosis and treatment


Amsterdam, The Netherlands – Royal Philips (NSYE: PHG, AEX: PHIA) today announced that it will be showcasing solutions at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2016 Annual Meeting in San Diego, Calif., highlighting Philips’ legacy of innovation. Recognizing molecular imaging’s unique ability to transform healthcare, Philips has developed high-quality imaging solutions that aim to increase diagnostic confidence, enhance the patient experience and care, and lower costs – expanding the advancements seen over the past 125 years as a company.


“Our dedication to developing solutions for enhanced diagnosis and treatment can be seen across Philips, demonstrated by our continued commitment to deliver health technology to drive better outcomes across the health continuum,” said Kirill Shalyaev, Ph.D., Vice President and General Manager, Advanced Molecular Imaging, Philips. “Philips’ proven solutions and advanced innovations in molecular imaging are enabling fast and confident decision making.”


Nuclear medicine technology has significantly evolved over the years – growing from scanner-only equipment to solutions that integrate quality, quantification and analytics. Ten years ago, also in San Diego, Philips introduced the first commercial Time-of-Flight PET/CT. Over the last decade, this technology has continued to improve and today, time-of-flight is faster, better, and digital. This year, over 20 oral and poster sessions featuring Philips’ digital photon counting PET system will be presented at the SNMMI meeting, highlighting the technology’s full range of capabilities and Philips’ work with academic partners.


“The Wright Center of Innovation team at The Ohio State University and Philips have been very successful partners in the clinical evaluation of the next generation digital PET/CT,” said Michael V. Knopp, MD, PhD, Professor of Radiology at The Ohio State University Wexner Medical Center. “In this year’s SNMMI Annual Meeting, we will present over 20 scientific presentations and posters on these efforts demonstrating performance and benefits of PET digital photon counting in the areas of lesion detectability, radiation dose management and quantitative imaging.”

 

As our population continues to age and exponentially grows in the coming years, coinciding with the prevalence of multiple chronic and complex diseases such as cancer, dementia and cardiac diseases, health imaging will require a more integrated and inter-disciplinary approach toward treatment. Given the unique clinical insights it provides, molecular imaging will play even more of a critical role in addressing complex diseases – as a result, the advanced data and analytics found in these technologies will be essential to improving patient care.


Philips’ SNMMI exhibit (Booth 1330, Hall E) will feature the latest solutions and technologies driving nuclear medicine, and will highlight the following milestones:

 

  • A decade of Time of Flight – Launched ten years ago, Time-of-Flight technology continues to hold the promise of better PET imaging. Since it was first brought to market in 2006, it has grown to be an integral piece in Philips’ portfolio of PET/CT solutions. Today, time-of-flight is faster, better and digital in products such as Vereos, the world’s first fully digital PET/CT. Time-of-Flight technology is now bridging innovation with digital architecture available in Philips solutions – meaning high quality images and enhanced lesion detectability.
  • Advanced data sharing – Data sharing gives physicians the power to visualize, diagnose and communicate across clinical domains and imaging modalities with one automated workflow. Philips’ latest edition of its advanced data sharing, analytics and visualization platform, Intellispace 8.0, helps physicians detect, diagnose and follow up on treatment of diseases, offering a comprehensive advanced visualization suite for multi-modality tumor tracking, characterization and assessment.
  • Flexibility of PET/CT – Philips PET/CT systems allow physicians to go beyond current limitations in standard PET/CT imaging, with capabilities such as digital imaging, and can now meet a wide range of clinical and economic needs in CT lung cancer screening.

 

For more information on Philips' molecular imaging solutions, and to learn more about the company’s presence at SNMMI 2016, visit Booth 1330, Hall E; www.philips.com/snmmi and follow the conversation on @PhilipsLiveFrom.

For further information, please contact:

Adrienne Smith
Philips Diagnostic Imaging
Tel: +1 781-277-1170 
Email: Adrienne.Smith@philips.com

 

Kathy O’Reilly

Philips Group Communications

Tel: +1 978-221-8919

Email: Kathy.oreilly@philips.com

@kathyoreilly

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Headquartered in the Netherlands, Philips' health technology portfolio generated 2015 sales of EUR 16.8 billion and employs approximately 69,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.